Global Healthcare Analyst

Tina Banerjee

Equity research analyst having 15+ years of experience, with an interest on fundamentally strong global healthcare companies. I have been helping investors to find future winners in healthcare space to grow their wealth by focusing on the strength and potential of the business models of the companies. My initiating coverage reports and pitch help investors to know ‘what to buy’, ‘why to buy’, and ‘when to buy’. My clients always remain on top of the sector with the help of my timely and detailed notes on earnings or any news update. I also provide broader view on the entire healthcare sector through periodic thematic reports.

Dr Lal PathLabs (DLPL IN): Strong Trajectory in Non-COVID Business; Positive Industry Outlook

Dr Lal PathLabs Ltd (DLPL IN): Volume Driven Topline Growth and Margin Improvement Continued in Q2

Dr Lal PathLabs Ltd (DLPL IN): Poised for Next Level of Growth Amid Easing Price Competition

Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/dr-lal-pathlabs-ltd" target="_blank" data-smartkarma-citation="entities:26927:1" rel="noopener">Dr Lal PathLabs Ltd (DLPL IN)</a> started FY26 on a strong note, achieving double-digit improvement in all key parameters, mainly driven by volume resulting from expanding geographic presence.</li>
<li>Steady secular rise in the number of tests as well as sample per patient is helping DLPL to deliver healthy top and bottom line growth, without indulging in price hike.</li>
<li>For FY26, the company guided for 11–12% revenue growth (acceleration from 10.5% revenue growth in FY25) and expects FY26 EBITDA margin will be better than initial expectation of 27%.</li>
</ul>



Dr Lal PathLabs Ltd (DLPL IN) started FY26 on a strong note, achieving double-digit improvement in all key parameters, mainly driven by volume resulting from expanding geographic presence.
Steady secular rise in the number of tests as well as sample per patient is helping DLPL to deliver healthy top and bottom line growth, without indulging in price hike.
For FY26, the company guided for 11–12% revenue growth (acceleration from 10.5% revenue growth in FY25) and expects FY26 EBITDA margin will be better than initial expectation of 27%.


Dr Lal PathLabs Ltd (DLPL IN): Here’s Why Growth to Accelerate and Margin to Improve